Back to News
Market Impact: 0.3
Anika Therapeutics Reports Third Quarter 2026 Revenue of $30.6 million
Source: Nasdaq
Corporate EarningsCompany Fundamentals
Anika Therapeutics reported third-quarter 2026 revenue of $30.6 million, up 10% from $27.8 million in the prior-year period. The available article text attributes the growth to its Commercial Channel but ends before providing further detail.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ANIK0.40
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FTSE 100 today: Stocks slump as global tech rout deepens